Anzeige
Mehr »
Login
Dienstag, 14.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
235 Leser
Artikel bewerten:
(1)

Maple Leaf Short Duration 2022-II Flow-Through Limited Partnership: Rollover Transaction Completed October 4, 2023 - Maple Leaf Short Duration 2022-II Flow-Through LP

Finanznachrichten News

VANCOUVER, BC / ACCESSWIRE / October 5, 2023 / Maple Leaf Short Duration 2022-II Flow-Through Limited Partnership - National Class and Quebec Class (the "Partnership") is pleased to announce that on October 4, 2023, the Partnership completed its rollover transaction whereby the assets of the Partnership were transferred to the Maple Leaf Resource Class (CDO 100- Class A or CDO103- Class F) mutual fund (the "Resource Mutual Fund") in exchange for Series A or Series F shares of the Resource Mutual Fund.

NATIONAL CLASS A (CUISP: 56532T105) ROLLOVER DETAILS
The final net asset value per National Class A Partnership unit was $15.88. Series A shares of the Resource Mutual Fund were issued at a net asset value of $2.01017 each. Accordingly, each holder of National Class A Partnership units received 7.90125 Resource Mutual Fund shares for each National Class A Partnership unit held.

NATIONAL CLASS F (CUISP: 56532T204) ROLLOVER DETAILS
The final net asset value per National Class F Partnership unit was $16.49. Series F shares of the Resource Mutual Fund were issued at a net asset value of $2.01017 each. Accordingly, each holder of National Class F Partnership units received 8.20102 Resource Mutual Fund shares for each National Class F Partnership unit held.

QUEBEC CLASS A (CUSIP: 56532T303) ROLLOVER DETAILS
The final net asset value per Quebec Class A Partnership unit was $12.51. Series A Resource Mutual Fund shares were issued at a net asset value of $2.01017 each. Accordingly, each holder of Quebec Class A Partnership units received 6.22455 Resource Mutual Funds shares for each Quebec Class A Partnership unit held.

QUEBEC CLASS F (CUSIP: 56532T402) ROLLOVER DETAILS
The final net asset value per Quebec Class F Partnership unit was $12.99. Series F Resource Mutual Fund shares were issued at a net asset value of $2.01017 each. Accordingly, each holder of Quebec Class F Partnership units received 6.46072 Resource Mutual Funds shares for each Quebec Class F Partnership unit held.

Resource Mutual Fund shares will be deposited into investors' brokerage accounts.
Investors should note:

  • Transactions may only be executed once the dealer has processed the rollover transaction and the Resource Mutual Fund shares show in your account. It typically takes 2-5 days for dealers to process the rollover transaction.
  • The shares of the Resource Mutual Fund are qualified investment for RRSPs, RRIFs, RESPs, DPSPs, RDSPs and TFSAs.
  • Redeeming the Resource Mutual Fund shares for cash will incur a capital gain tax liability.

ABOUT MAPLE LEAF
Maple Leaf is a privately held, independent firm whose executive members have participated in the formation of over $900 million of capital based on energy and resource focused alternative investment products for Canadian resident investors.

ADDITIONAL INFORMATION
Additional information about the Mutual Fund is available in the Mutual Fund's simplified prospectus, annual information form, management reports of fund performance and financial statements. You can obtain a copy of these documents at your request and at no cost by calling toll free 1-866-688-5750, or from your financial advisor, or by e-mailing info@MapleLeafFunds.ca, or by download at www.MapleLeafFunds.ca. These documents and other information about the Mutual Fund will also be available at SEDAR (the System for Electronic Document Analysis and Retrieval established by the Canadian Securities Administrators) at www.sedar.com.

For Further Information
For further information, please contact Emily Burkart, Managing Director. Capital Markets.

MAPLE LEAF FLOW-THROUGH PROGRAMS

Tel: 604.684.5742 | Toll Free: 866.688.5750
Email: info@MapleLeafFunds.ca | Web: www.MapleLeafFunds.ca

This release is provided for information purposes only and shall not constitute an offer to sell or the solicitation of any offer to buy the securities. No securities regulatory authority has expressed an opinion about the merits of the shares of the Resource Mutual Fund and Income Mutual Fund and it is an offense to claim otherwise. Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the simplified prospectus and consult your financial advisor to determine if these investments are suitable for you. Mutual Funds are not guaranteed, their values change frequently and past performance may not be repeated.

SOURCE: Maple Leaf Short Duration 2022-II Flow-Through Limited Partnership

View source version on accesswire.com:
https://www.accesswire.com/790470/rollover-transaction-completed-october-4-2023--maple-leaf-short-duration-2022-ii-flow-through-lp-national-quebec-class

© 2023 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.